Glut-1 Expression Correlates with Basal-like Breast Cancer
Glut-1 Expression Correlates with Basal-like Breast Cancer
复制标题
DOI：
10.1593/tlo.11256
复制
发表时间：
2011-12-01
影响因子：
5
通讯作者：
Ali-Fehmi, Rouba
中科院分区：
文献类型：
--
作者：
Hussein, Yaser R.;Bandyopadhyay, Sudeshna;Ali-Fehmi, Rouba
简介：葡萄糖转运蛋白1（Glut-1）是一种促进性葡萄糖转运蛋白，在包括乳腺癌在内的许多癌症中表达。基底细胞样乳腺癌（BLBC）是一种预后不良的高危疾病，缺乏靶向治疗的益处。本研究的目的是表征与非BLBC相比，BLBC患者中Glut-1的免疫组织化学（IHC）表达。材料和方法：我们从我们的数据库中确定了523例浸润性乳腺癌。本文回顾性分析了其临床病理特征和生物学指标，包括雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（Her 2）的状态。使用标准程序在组织微阵列上进行细胞角蛋白5/6（CK 5/6）、表皮生长因子受体（EGFR）、p53和Glut-1的IHC染色。BLBC定义为ER-、PR-、Her 2-和CK 5/6+和/或EGFR+。结果：在提供信息的病例中，14.7%被归类为BLBC，85.3%被归类为非BLBC。55个BLBC中有42个（76.4%）表达Glut-1，而231个非BLBC中只有55个（23.8%）显示Glut-1的免疫染色（P < .001）。总的来说，Glut-1表达与高组织学分级、ER阴性、PR阴性、CK 5/6阳性、EGFR表达和高p53表达显著相关（P <0.001）。然而，Glut-1免疫染色与患者的结局之间没有相关性。结论：我们的研究结果表明Glut-1与BLBC显著相关，可能是这种侵袭性乳腺癌亚组的潜在治疗靶点，这值得进一步研究。
INTRODUCTION: Glucose transporter 1 (Glut-1) is a facilitative glucose transporter expressed in many cancers including breast cancer. Basal-like breast cancer (BLBC) is a high-risk disease associated with poor prognosis and lacks the benefit of targeted therapy. The aim of this study was to characterize the immunohistochemical (IHC) expression of Glut-1 in patients with BLBC compared with non-BLBC. MATERIALS AND METHODS: We identified 523 cases of invasive breast carcinoma from our database. The clinicopathologic findings and the biologic markers including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2) status were reviewed. IHC stains for cytokeratin 5/6 (CK5/6), epidermal growth factor receptor (EGFR), p53, and Glut-1 were performed on tissue microarray using standard procedures. BLBC was defined as ER-, PR-, Her2-, and CK5/6+ and/or EGFR+. RESULTS: Of informative cases, 14.7% were categorized as BLBC versus 85.3% as non-BLBC. Glut-1 was expressed in 42 (76.4%) of 55 BLBCs, whereas only 55 (23.8%) of 231 non-BLBCs showed immunostaining for Glut-1 (P < .001). Overall, Glut-1 expression was significantly associated with high histologic grade, ER negativity, PR negativity, CK5/6 positivity, EGFR expression, and high p53 expression (P < .001). However, there was no correlation between Glut-1 immunostaining and patient's outcome. CONCLUSIONS: Our results show that Glut-1 is significantly associated with BLBC and might be a potential therapeutic target for this aggressive subgroup of breast cancer, and this warrants further investigations.